Photo from wikipedia
A phase I open‐label study assessed the effect of multiple oral doses of a potent CYP3A4 inhibitor (itraconazole) and inducer (rifampicin) on the pharmacokinetic profile of a single oral dose… Click to show full abstract
A phase I open‐label study assessed the effect of multiple oral doses of a potent CYP3A4 inhibitor (itraconazole) and inducer (rifampicin) on the pharmacokinetic profile of a single oral dose of senaparib, a novel, highly potent poly‐(ADP‐ribose) polymerase 1/2 inhibitor and CYP3A4 substrate, in Chinese healthy male volunteers (HMV).
Keywords:
effect;
cyp3a4 inhibitor;
inducer;
inhibitor;
drug;
study
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!